25 XP   0   0   10

Allergy Therapeutics
Buy, Hold or Sell?

Let's analyse Allergy Therapeutics together

PenkeI guess you are interested in Allergy Therapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Allergy Therapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Allergy Therapeutics

I send you an email if I find something interesting about Allergy Therapeutics.

Quick analysis of Allergy Therapeutics (30 sec.)










What can you expect buying and holding a share of Allergy Therapeutics? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p0.04
Expected worth in 1 year
p-2.95
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
p-3.00
Return On Investment
-105.1%

For what price can you sell your share?

Current Price per Share
p2.85
Expected price per share
p2.7 - p3
How sure are you?
50%

1. Valuation of Allergy Therapeutics (5 min.)




Live pricePrice per Share (EOD)

p2.85

Intrinsic Value Per Share

p-14.12 - p-4.45

Total Value Per Share

p-14.08 - p-4.40

2. Growth of Allergy Therapeutics (5 min.)




Is Allergy Therapeutics growing?

Current yearPrevious yearGrowGrow %
How rich?$2.5m$47m-$44.4m-1,727.9%

How much money is Allergy Therapeutics making?

Current yearPrevious yearGrowGrow %
Making money-$53.6m-$17.1m-$36.5m-68.0%
Net Profit Margin-72.3%-18.9%--

How much money comes from the company's main activities?

3. Financial Health of Allergy Therapeutics (5 min.)




What can you expect buying and holding a share of Allergy Therapeutics? (5 min.)

Welcome investor! Allergy Therapeutics's management wants to use your money to grow the business. In return you get a share of Allergy Therapeutics.

What can you expect buying and holding a share of Allergy Therapeutics?

First you should know what it really means to hold a share of Allergy Therapeutics. And how you can make/lose money.

Speculation

The Price per Share of Allergy Therapeutics is p2.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allergy Therapeutics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allergy Therapeutics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p0.04. Based on the TTM, the Book Value Change Per Share is p-0.75 per quarter. Based on the YOY, the Book Value Change Per Share is p-0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allergy Therapeutics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.01-0.5%-0.01-0.5%0.00-0.1%0.00-0.1%0.00-0.1%
Usd Book Value Change Per Share-0.01-0.3%-0.01-0.3%0.00-0.1%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.3%-0.01-0.3%0.00-0.1%0.000.0%0.000.0%
Usd Price Per Share0.01-0.01-0.26-0.19-0.23-
Price to Earnings Ratio-0.98--0.98--71.79-125.43-1,050.77-
Price-to-Total Gains Ratio-1.40--1.40--91.83-62.13--167.51-
Price to Book Ratio24.22-24.22-26.19-21.59-31.39-
Price-to-Total Gains Ratio-1.40--1.40--91.83-62.13--167.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.03551385
Number of shares28158
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (28158 shares)-262.79-30.87
Gains per Year (28158 shares)-1,051.18-123.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1051-10610-123-133
20-2102-21120-247-256
30-3154-31630-370-379
40-4205-42140-494-502
50-5256-52650-617-625
60-6307-63160-741-748
70-7358-73670-864-871
80-8409-84180-988-994
90-9461-94690-1111-1117
100-10512-105200-1235-1240

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%10.012.00.045.5%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%12.010.00.054.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.022.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%12.010.00.054.5%

Fundamentals of Allergy Therapeutics

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-19 03:30:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Allergy Therapeutics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Allergy Therapeutics earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -72.3% means that -0.72 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allergy Therapeutics:

  • The MRQ is -72.3%. The company is making a huge loss. -2
  • The TTM is -72.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-72.3%TTM-72.3%0.0%
TTM-72.3%YOY-18.9%-53.4%
TTM-72.3%5Y-14.8%-57.5%
5Y-14.8%10Y-11.4%-3.4%
1.1.2. Return on Assets

Shows how efficient Allergy Therapeutics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • -64.5% Return on Assets means that Allergy Therapeutics generated -0.65 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allergy Therapeutics:

  • The MRQ is -64.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -64.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-64.5%TTM-64.5%0.0%
TTM-64.5%YOY-18.9%-45.6%
TTM-64.5%5Y-13.4%-51.1%
5Y-13.4%10Y-10.6%-2.8%
1.1.3. Return on Equity

Shows how efficient Allergy Therapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2,084.8% Return on Equity means Allergy Therapeutics generated -20.85 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allergy Therapeutics:

  • The MRQ is -2,084.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2,084.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2,084.8%TTM-2,084.8%0.0%
TTM-2,084.8%YOY-36.5%-2,048.3%
TTM-2,084.8%5Y-418.0%-1,666.8%
5Y-418.0%10Y-216.9%-201.1%

1.2. Operating Efficiency of Allergy Therapeutics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Allergy Therapeutics is operating .

  • Measures how much profit Allergy Therapeutics makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -58.5% means the company generated -0.58  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allergy Therapeutics:

  • The MRQ is -58.5%. The company is operating very inefficient. -2
  • The TTM is -58.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-58.5%TTM-58.5%0.0%
TTM-58.5%YOY-17.9%-40.6%
TTM-58.5%5Y-12.3%-46.2%
5Y-12.3%10Y-9.3%-3.0%
1.2.2. Operating Ratio

Measures how efficient Allergy Therapeutics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.58 means that the operating costs are 1.58 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.585. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.585. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.585TTM1.5850.000
TTM1.585YOY1.179+0.406
TTM1.5855Y1.123+0.462
5Y1.12310Y1.094+0.029

1.3. Liquidity of Allergy Therapeutics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.81 means the company has 1.81 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.806. The company is able to pay all its short-term debts. +1
  • The TTM is 1.806. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.806TTM1.8060.000
TTM1.806YOY2.348-0.542
TTM1.8065Y2.624-0.818
5Y2.62410Y2.766-0.142
1.3.2. Quick Ratio

Measures if Allergy Therapeutics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.18 means the company can pay off 1.18 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allergy Therapeutics:

  • The MRQ is 1.181. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.181. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.181TTM1.1810.000
TTM1.181YOY1.716-0.535
TTM1.1815Y2.010-0.829
5Y2.01010Y1.532+0.479

1.4. Solvency of Allergy Therapeutics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Allergy Therapeutics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Allergy Therapeutics to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.97 means that Allergy Therapeutics assets are financed with 96.9% credit (debt) and the remaining percentage (100% - 96.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Allergy Therapeutics:

  • The MRQ is 0.969. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.969. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.969TTM0.9690.000
TTM0.969YOY0.482+0.487
TTM0.9695Y0.569+0.400
5Y0.56910Y0.512+0.057
1.4.2. Debt to Equity Ratio

Measures if Allergy Therapeutics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 3,131.8% means that company has 31.32 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allergy Therapeutics:

  • The MRQ is 31.318. The company is unable to pay all its debts with equity. -1
  • The TTM is 31.318. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ31.318TTM31.3180.000
TTM31.318YOY0.932+30.386
TTM31.3185Y6.972+24.346
5Y6.97210Y3.920+3.051

2. Market Valuation of Allergy Therapeutics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Allergy Therapeutics generates.

  • Above 15 is considered overpriced but always compare Allergy Therapeutics to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -0.98 means the investor is paying -0.98 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allergy Therapeutics:

  • The EOD is -2.662. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.981. Based on the earnings, the company is expensive. -2
  • The TTM is -0.981. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.662MRQ-0.981-1.681
MRQ-0.981TTM-0.9810.000
TTM-0.981YOY-71.794+70.813
TTM-0.9815Y125.427-126.408
5Y125.42710Y1,050.774-925.347
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allergy Therapeutics:

  • The EOD is -3.817. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.406. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.406. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.817MRQ-1.406-2.411
MRQ-1.406TTM-1.4060.000
TTM-1.406YOY-57.613+56.206
TTM-1.4065Y95.304-96.710
5Y95.30410Y112.292-16.988
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Allergy Therapeutics is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Allergy Therapeutics:

  • The EOD is 65.752. Based on the equity, the company is expensive. -2
  • The MRQ is 24.224. Based on the equity, the company is expensive. -2
  • The TTM is 24.224. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD65.752MRQ24.224+41.528
MRQ24.224TTM24.2240.000
TTM24.224YOY26.189-1.965
TTM24.2245Y21.595+2.630
5Y21.59510Y31.395-9.800
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Allergy Therapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.749-0.7490%-0.226-70%-0.088-88%-0.026-96%
Book Value Per Share--0.0430.0430%0.792-95%0.712-94%0.635-93%
Current Ratio--1.8061.8060%2.348-23%2.624-31%2.766-35%
Debt To Asset Ratio--0.9690.9690%0.482+101%0.569+70%0.512+89%
Debt To Equity Ratio--31.31831.3180%0.932+3262%6.972+349%3.920+699%
Dividend Per Share----0%-0%-0%-0%
Eps---1.071-1.0710%-0.289-73%-0.216-80%-0.154-86%
Free Cash Flow Per Share---0.747-0.7470%-0.360-52%-0.145-81%-0.111-85%
Free Cash Flow To Equity Per Share---0.119-0.1190%-0.416+249%0.000-26359%0.071-267%
Gross Profit Margin--1.5501.5500%2.888-46%-2.520+263%-17.376+1221%
Intrinsic Value_10Y_max---4.448--------
Intrinsic Value_10Y_min---14.122--------
Intrinsic Value_1Y_max---0.184--------
Intrinsic Value_1Y_min---0.608--------
Intrinsic Value_3Y_max---0.752--------
Intrinsic Value_3Y_min---2.536--------
Intrinsic Value_5Y_max---1.560--------
Intrinsic Value_5Y_min---5.228--------
Market Cap13584353817.600+63%5004761932.8005004761932.8000%98903628672.000-95%71305941442.560-93%87726327022.080-94%
Net Profit Margin---0.723-0.7230%-0.189-74%-0.148-80%-0.114-84%
Operating Margin---0.585-0.5850%-0.179-69%-0.123-79%-0.093-84%
Operating Ratio--1.5851.5850%1.179+34%1.123+41%1.094+45%
Pb Ratio65.752+63%24.22424.2240%26.189-8%21.595+12%31.395-23%
Pe Ratio-2.662-171%-0.981-0.9810%-71.794+7220%125.427-101%1050.774-100%
Price Per Share2.850+63%1.0501.0500%20.750-95%14.960-93%18.405-94%
Price To Free Cash Flow Ratio-3.817-171%-1.406-1.4060%-57.613+3996%95.304-101%112.292-101%
Price To Total Gains Ratio-3.805-171%-1.402-1.4020%-91.833+6450%62.133-102%-167.509+11848%
Quick Ratio--1.1811.1810%1.716-31%2.010-41%1.532-23%
Return On Assets---0.645-0.6450%-0.189-71%-0.134-79%-0.106-84%
Return On Equity---20.848-20.8480%-0.365-98%-4.180-80%-2.169-90%
Total Gains Per Share---0.749-0.7490%-0.226-70%-0.088-88%-0.026-96%
Usd Book Value--2574442.6002574442.6000%47058966.500-95%42294378.540-94%37703746.140-93%
Usd Book Value Change Per Share---0.009-0.0090%-0.003-70%-0.001-88%0.000-96%
Usd Book Value Per Share--0.0010.0010%0.010-95%0.009-94%0.008-93%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.013-0.0130%-0.004-73%-0.003-80%-0.002-86%
Usd Free Cash Flow---44342468.500-44342468.5000%-21391798.700-52%-8615036.960-81%-6606697.590-85%
Usd Free Cash Flow Per Share---0.009-0.0090%-0.004-52%-0.002-81%-0.001-85%
Usd Free Cash Flow To Equity Per Share---0.001-0.0010%-0.005+249%0.000-26359%0.001-267%
Usd Market Cap169274632.921+63%62364338.44562364338.4450%1232438116.882-95%888543336.316-93%1093157761.022-94%
Usd Price Per Share0.036+63%0.0130.0130%0.259-95%0.186-93%0.229-94%
Usd Profit---53670773.100-53670773.1000%-17166273.600-68%-10825119.920-80%-8183512.530-85%
Usd Revenue--74251360.70074251360.7000%90676204.800-18%91864236.540-19%79100558.850-6%
Usd Total Gains Per Share---0.009-0.0090%-0.003-70%-0.001-88%0.000-96%
 EOD+5 -3MRQTTM+0 -0YOY+5 -295Y+4 -3010Y+6 -28

3.2. Fundamental Score

Let's check the fundamental score of Allergy Therapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.662
Price to Book Ratio (EOD)Between0-165.752
Net Profit Margin (MRQ)Greater than0-0.723
Operating Margin (MRQ)Greater than0-0.585
Quick Ratio (MRQ)Greater than11.181
Current Ratio (MRQ)Greater than11.806
Debt to Asset Ratio (MRQ)Less than10.969
Debt to Equity Ratio (MRQ)Less than131.318
Return on Equity (MRQ)Greater than0.15-20.848
Return on Assets (MRQ)Greater than0.05-0.645
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Allergy Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.968
Ma 20Greater thanMa 502.865
Ma 50Greater thanMa 1002.687
Ma 100Greater thanMa 2002.366
OpenGreater thanClose2.850
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Debt  -2,500,40022,100-2,478,300-431,800-2,910,1001,911,500-998,6003,113,0002,114,400
Net Tangible Assets  3,271,800632,9003,904,700473,4004,378,100-1,041,9003,336,200-4,254,500-918,300



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in GBP. All numbers in thousands.

Summary
Total Assets66,769
Total Liabilities64,703
Total Stockholder Equity2,066
 As reported
Total Liabilities 64,703
Total Stockholder Equity+ 2,066
Total Assets = 66,769

Assets

Total Assets66,769
Total Current Assets33,526
Long-term Assets33,243
Total Current Assets
Cash And Cash Equivalents 14,845
Net Receivables 7,088
Inventory 11,593
Total Current Assets  (as reported)33,526
Total Current Assets  (calculated)33,526
+/-0
Long-term Assets
Property Plant Equipment 23,241
Goodwill 3,346
Intangible Assets 4,400
Long-term Assets Other 2,256
Long-term Assets  (as reported)33,243
Long-term Assets  (calculated)33,243
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,565
Long-term Liabilities46,138
Total Stockholder Equity2,066
Total Current Liabilities
Short-term Debt 1,803
Short Long Term Debt 648
Accounts payable 4,090
Other Current Liabilities 12,672
Total Current Liabilities  (as reported)18,565
Total Current Liabilities  (calculated)19,213
+/- 648
Long-term Liabilities
Capital Lease Obligations 8,902
Other Liabilities 19,532
Long-term Liabilities  (as reported)46,138
Long-term Liabilities  (calculated)28,434
+/- 17,704
Total Stockholder Equity
Common Stock689
Retained Earnings -121,742
Accumulated Other Comprehensive Income 4,089
Other Stockholders Equity 119,030
Total Stockholder Equity (as reported)2,066
Total Stockholder Equity (calculated)2,066
+/-0
Other
Capital Stock689
Cash and Short Term Investments 14,845
Common Stock Shares Outstanding 1,456,288
Current Deferred Revenue-1,803
Liabilities and Stockholders Equity 66,769
Net Debt 21,144
Net Invested Capital 22,713
Net Tangible Assets -9,183
Net Working Capital 15,154
Property Plant and Equipment Gross 23,977
Short Long Term Debt Total 35,989



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-30
> Total Assets 
9,676
11,149
11,234
26,660
37,880
23,994
23,183
22,077
29,115
30,621
27,754
28,964
28,398
50,699
56,679
57,183
51,016
68,497
86,225
88,089
72,948
66,769
66,76972,94888,08986,22568,49751,01657,18356,67950,69928,39828,96427,75430,62129,11522,07723,18323,99437,88026,66011,23411,1499,676
   > Total Current Assets 
3,576
5,496
5,567
20,981
31,088
14,043
11,317
9,442
14,804
14,914
13,034
14,458
14,211
33,789
37,612
37,459
30,928
46,625
55,170
57,858
42,393
33,526
33,52642,39357,85855,17046,62530,92837,45937,61233,78914,21114,45813,03414,91414,8049,44211,31714,04331,08820,9815,5675,4963,576
       Cash And Cash Equivalents 
56
1,267
1,457
15,080
23,860
5,696
2,298
0
4,520
1,048
903
1,257
2,029
21,199
23,406
22,122
15,533
27,440
36,962
40,273
20,515
14,845
14,84520,51540,27336,96227,44015,53322,12223,40621,1992,0291,2579031,0484,52002,2985,69623,86015,0801,4571,26756
       Short-term Investments 
0
0
0
0
0
63
3
0
0
0
483
2
345
783
0
404
0
0
0
0
0
0
0000004040783345248300036300000
       Net Receivables 
0
1,127
2,011
2,812
2,482
2,651
2,699
2,284
2,663
5,746
3,761
5,404
4,387
4,230
4,678
6,271
5,405
8,492
8,076
6,222
10,468
7,088
7,08810,4686,2228,0768,4925,4056,2714,6784,2304,3875,4043,7615,7462,6632,2842,6992,6512,4822,8122,0111,1270
       Inventory 
1,865
1,915
1,825
2,741
3,651
4,911
5,817
6,002
6,894
7,087
6,651
6,014
6,469
6,747
7,692
7,484
8,808
9,409
10,132
10,838
11,410
11,593
11,59311,41010,83810,1329,4098,8087,4847,6926,7476,4696,0146,6517,0876,8946,0025,8174,9113,6512,7411,8251,9151,865
   > Long-term Assets 
6,100
5,653
5,667
5,679
6,792
9,951
11,866
12,635
14,311
15,707
14,720
14,506
14,187
16,910
19,067
19,724
20,088
21,872
31,055
30,231
30,555
33,243
33,24330,55530,23131,05521,87220,08819,72419,06716,91014,18714,50614,72015,70714,31112,63511,8669,9516,7925,6795,6675,6536,100
       Property Plant Equipment 
1,342
1,221
1,650
2,111
3,637
5,931
6,883
7,191
8,938
8,809
7,555
7,337
7,030
8,750
9,667
9,673
10,096
11,481
20,417
19,717
20,190
23,241
23,24120,19019,71720,41711,48110,0969,6739,6678,7507,0307,3377,5558,8098,9387,1916,8835,9313,6372,1111,6501,2211,342
       Goodwill 
0
3,220
2,945
2,617
4,977
2,295
2,468
2,555
2,496
2,624
2,489
2,560
2,480
2,980
3,271
3,390
3,406
3,432
3,467
3,343
3,347
3,346
3,3463,3473,3433,4673,4323,4063,3903,2712,9802,4802,5602,4892,6242,4962,5552,4682,2954,9772,6172,9453,2200
       Intangible Assets 
4,758
4,432
4,017
951
-1,822
1,159
1,073
1,065
860
1,781
2,107
1,350
1,291
2,020
2,084
2,069
1,543
1,408
4,736
4,754
5,035
4,400
4,4005,0354,7544,7361,4081,5432,0692,0842,0201,2911,3502,1071,7818601,0651,0731,159-1,8229514,0174,4324,758
       Other Assets 
0
0
0
0
0
0
1,400
1,824
2,017
2,493
2,569
3,259
3,386
3,160
4,045
4,592
5,043
5,551
0
5,760
0
5,813
5,81305,76005,5515,0434,5924,0453,1603,3863,2592,5692,4932,0171,8241,400000000
> Total Liabilities 
14,074
5,602
4,158
6,576
5,178
15,398
34,473
45,253
25,229
28,482
13,162
14,293
13,323
16,230
26,355
27,218
27,982
30,939
42,442
39,554
35,183
64,703
64,70335,18339,55442,44230,93927,98227,21826,35516,23013,32314,29313,16228,48225,22945,25334,47315,3985,1786,5764,1585,60214,074
   > Total Current Liabilities 
4,593
3,997
3,277
6,121
4,939
10,864
8,105
21,774
9,984
11,147
7,747
7,620
6,474
7,420
12,520
14,020
14,631
16,859
18,227
18,230
18,053
18,565
18,56518,05318,23018,22716,85914,63114,02012,5207,4206,4747,6207,74711,1479,98421,7748,10510,8644,9396,1213,2773,9974,593
       Short-term Debt 
0
500
278
0
0
0
2,422
11,652
1,109
2,793
1,426
288
49
251
295
391
644
694
2,264
1,755
2,268
1,803
1,8032,2681,7552,264694644391295251492881,4262,7931,10911,6522,4220002785000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
49
251
295
391
644
694
829
963
952
648
64895296382969464439129525149000000000000
       Accounts payable 
0
1,196
827
1,478
1,671
4,612
2,312
3,742
3,948
3,821
2,553
3,050
2,464
2,819
3,110
2,881
3,193
15,736
2,217
2,897
4,282
4,090
4,0904,2822,8972,21715,7363,1932,8813,1102,8192,4643,0502,5533,8213,9483,7422,3124,6121,6711,4788271,1960
       Other Current Liabilities 
0
2,301
2,172
4,643
3,268
6,102
3,371
6,380
4,927
4,533
3,768
4,282
3,961
332
0
593
10,794
429
13,746
13,578
11,503
12,672
12,67211,50313,57813,74642910,79459303323,9614,2823,7684,5334,9276,3803,3716,1023,2684,6432,1722,3010
   > Long-term Liabilities 
9,481
1,605
881
455
239
4,534
26,368
23,479
15,245
17,335
5,415
6,673
6,849
8,810
13,835
13,198
13,351
14,080
24,215
21,324
17,130
46,138
46,13817,13021,32424,21514,08013,35113,19813,8358,8106,8496,6735,41517,33515,24523,47926,3684,5342394558811,6059,481
       Other Liabilities 
0
241
214
455
239
2,373
2,955
4,224
4,649
4,773
5,153
6,514
6,713
7,377
10,765
10,262
10,937
12,338
14,300
11,907
8,869
19,532
19,5328,86911,90714,30012,33810,93710,26210,7657,3776,7136,5145,1534,7734,6494,2242,9552,3732394552142410
> Total Stockholder Equity
0
6,161
7,076
20,084
32,702
8,355
0
0
3,886
2,139
14,592
14,671
15,075
34,469
30,324
29,965
23,034
37,558
43,783
48,535
37,765
2,066
2,06637,76548,53543,78337,55823,03429,96530,32434,46915,07514,67114,5922,1393,886008,35532,70220,0847,0766,1610
   Common Stock
0
51
51
73
82
82
82
82
311
311
407
410
410
546
589
594
606
636
647
651
654
689
689654651647636606594589546410410407311311828282827351510
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
-2,889
-3,355
-3,652
-4,026
-4,632
-3,463
-4,473
-5,547
-6,259
-7,689
-9,013
-9,903
-10,624
-11,518
-12,997
-12,903
-14,344
-15,441
3,393
2,578
2,949
4,089
4,0892,9492,5783,393-15,441-14,344-12,903-12,997-11,518-10,624-9,903-9,013-7,689-6,259-5,547-4,473-3,463-4,632-4,026-3,652-3,355-2,889
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102,420
102,420
112,576
112,576
112,576
0
0
00112,576112,576112,576102,420102,420000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
45,479
41,834
41,249
156,698
158,522
156,099
112,576
112,576
112,576
119,030
119,030112,576112,576112,576156,099158,522156,69841,24941,83445,479000000000000



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue59,587
Cost of Revenue-26,896
Gross Profit32,69132,691
 
Operating Income (+$)
Gross Profit32,691
Operating Expense-67,542
Operating Income-34,851-34,851
 
Operating Expense (+$)
Research Development20,121
Selling General Administrative25,179
Selling And Marketing Expenses23,705
Operating Expense67,54269,005
 
Net Interest Income (+$)
Interest Income329
Interest Expense-2,158
Other Finance Cost-591
Net Interest Income-2,420
 
Pretax Income (+$)
Operating Income-34,851
Net Interest Income-2,420
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-42,622-27,080
EBIT - interestExpense = -37,009
-42,622
-40,913
Interest Expense2,158
Earnings Before Interest and Taxes (EBIT)-34,851-40,464
Earnings Before Interest and Taxes (EBITDA)-30,627
 
After tax Income (+$)
Income Before Tax-42,622
Tax Provision-1,197
Net Income From Continuing Ops-51,026-43,819
Net Income-43,071
Net Income Applicable To Common Shares-51,026
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses94,438
Total Other Income/Expenses Net-7,7712,420
 

Technical Analysis of Allergy Therapeutics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allergy Therapeutics. The general trend of Allergy Therapeutics is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allergy Therapeutics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allergy Therapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3 < 3 < 3.

The bearish price targets are: 2.7 > 2.7 > 2.7.

Tweet this
Allergy Therapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allergy Therapeutics. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allergy Therapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allergy Therapeutics. The current macd is 0.03640519.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Allergy Therapeutics price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Allergy Therapeutics. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Allergy Therapeutics price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Allergy Therapeutics Daily Moving Average Convergence/Divergence (MACD) ChartAllergy Therapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allergy Therapeutics. The current adx is 37.49.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Allergy Therapeutics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Allergy Therapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allergy Therapeutics. The current sar is 3.02210858.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Allergy Therapeutics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allergy Therapeutics. The current rsi is 54.97. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Allergy Therapeutics Daily Relative Strength Index (RSI) ChartAllergy Therapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allergy Therapeutics. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Allergy Therapeutics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Allergy Therapeutics Daily Stochastic Oscillator ChartAllergy Therapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allergy Therapeutics. The current cci is -17.95142555.

Allergy Therapeutics Daily Commodity Channel Index (CCI) ChartAllergy Therapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allergy Therapeutics. The current cmo is 7.65094769.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Allergy Therapeutics Daily Chande Momentum Oscillator (CMO) ChartAllergy Therapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allergy Therapeutics. The current willr is -42.85714286.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Allergy Therapeutics is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Allergy Therapeutics Daily Williams %R ChartAllergy Therapeutics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Allergy Therapeutics.

Allergy Therapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allergy Therapeutics. The current atr is 0.25294932.

Allergy Therapeutics Daily Average True Range (ATR) ChartAllergy Therapeutics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allergy Therapeutics. The current obv is 11,942,312.

Allergy Therapeutics Daily On-Balance Volume (OBV) ChartAllergy Therapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allergy Therapeutics. The current mfi is 39.11.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Allergy Therapeutics Daily Money Flow Index (MFI) ChartAllergy Therapeutics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allergy Therapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Allergy Therapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allergy Therapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.968
Ma 20Greater thanMa 502.865
Ma 50Greater thanMa 1002.687
Ma 100Greater thanMa 2002.366
OpenGreater thanClose2.850
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Allergy Therapeutics with someone you think should read this too:
  • Are you bullish or bearish on Allergy Therapeutics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allergy Therapeutics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allergy Therapeutics

I send you an email if I find something interesting about Allergy Therapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about Allergy Therapeutics.

Receive notifications about Allergy Therapeutics in your mailbox!